Cipla को भारत में उपयोग के लिए Moderna Vaccine आयात करने के लिए DCGI की मिली मंजूरी ।

Publish Date: 29 Jun, 2021 |

Amplifying the ongoing mass Vaccination drive for Covid-19, Pharma company Cipla has been given the nod to import Moderna's Covid vaccine for restricted emergency use in India. This will be the fourth vaccine available in India after Covaxin, Covishield and Russia's Sputnik V vaccine. Moderna will be given to people over the age of 18 years. 

As per the reports, the Cipla asked the DCGI for the approval of the vaccine for emergency use to people aged 18+. Meanwhile, another vaccine Pfizer used excessively in the USA and other foreign countries may also get approved in India. 

Let us tell you that Moderna's vaccine is tested to be 90 per cent effective against Covid.


Vaccines available in India 

Let us tell you that presently there are three vaccines that are allowed to be used in an emergency. The names include Covaxin and Covisheild developed in India and Sputnik vaccine developed in Russia. Well, with the approval of the Moderna vaccine which is based on mRNA technology, the ongoing vaccination drive in the country will hike up. 

Interval for the two doses of Modern Vaccine

According to the World Health Organization, the person administered with the Moderna vaccine will be given 2 doses in an interval of 28 days to 42 days. However, many countries have this difference as 12 weeks in their dosage with the purpose of giving vaccines to more and more people. The European Union, America and Switzerland have given permission to use this vaccine.

Vaccines exempt from trial in India

Earlier this month DCGI took a big decision in view of the shortage of corona vaccine in India. A notice was issued that the vaccines which have been approved by the US FDA or the World Health Organization for use in emergency services will not need trial in India. The vaccines which have been given to lakhs of people are exempted from the trial in India. 


Related videos

यह भी पढ़ें

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy.Accept